Path ID: DB00484_MESH_D012393_1

Concepts
Identifier | Name | Type |
---|---|---|
MESH:D000068438 | brimonidine | Drug |
UniProt:P08913 | Alpha-2A adrenergic receptor | Protein |
UniProt:P18089 | Alpha-2B adrenergic receptor | Protein |
UniProt:P18825 | Alpha-2C adrenergic receptor | Protein |
reactome:R-HSA-418594 | G alpha (i) signalling events | Pathway |
reactome:R-HSA-418597 | G alpha (z) signalling events | Pathway |
CHEBI:17489 | 3,5-cyclic AMP | ChemicalSubstance |
GO:0042310 | vasoconstriction | BiologicalProcess |
HP:0031284 | Flushing | PhenotypicFeature |
HP:0001041 | Facial erythema | PhenotypicFeature |
MESH:D012393 | Rosacea | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
Subject | Predicate | Object |
---|---|---|
Brimonidine | INCREASES ACTIVITY OF | Alpha-2A Adrenergic Receptor |
Brimonidine | INCREASES ACTIVITY OF | Alpha-2B Adrenergic Receptor |
Brimonidine | INCREASES ACTIVITY OF | Alpha-2C Adrenergic Receptor |
Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
G Alpha (I) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
G Alpha (Z) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
3,5-Cyclic Amp | NEGATIVELY CORRELATED WITH | Vasoconstriction |
Vasoconstriction | NEGATIVELY CORRELATED WITH | Facial Erythema |
Vasoconstriction | NEGATIVELY CORRELATED WITH | Flushing |
Flushing | POSITIVELY CORRELATED WITH | Rosacea |
Facial Erythema | POSITIVELY CORRELATED WITH | Rosacea |
Comment: The drug has an anti-inflammatory role which can help with treating some of the signs and symptoms of rosasea.
Reference: